AstraZeneca Stock Wavers As It Acquires Blood-Pressure Drugmaker – Investor's Business Daily

BREAKING: Market Closes Mixed As Dow, S&P 500 Shed Gains 

AstraZeneca (AZN) on Monday said it has agreed to buy CinCor Pharma (CINC), maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion. AstraZeneca stock edged up a fraction on the news while CINC stock rocketed higher.
The $26 per-share deal represents a 121% premium to Friday’s closing price of CINC stock, said AstraZeneca.
The upfront cash portion of the deal is valued at $1.3 billion for AstraZeneca stock. Under terms of the agreement, AstraZeneca will also pay $10 per share in cash based on a regulatory submission of baxdrostat, bringing the total value to $1.8 billion.
AstraZeneca will acquire the cash and marketable securities on CinCor’s balance sheet, which totaled $522 million as of Sept. 30.
“Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat,” AstraZeneca Executive Vice President Mene Pangalos said in a written statement. “Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”
On the stock market today, AstraZeneca stock edged up 0.1% to close at 70.90. Meanwhile, CINC stock soared nearly 144% to close at 28.74.
In the September quarter, cancer and diabetes drugs drove double-digit sales growth and a strong earnings beat for AstraZeneca. Overall, core AstraZeneca earnings grew 55% year over year to $1.67 per share. Total revenue rose 11% to $10.98 billion.
Part of the growth stemmed from the acquisition of Alexion Pharmaceuticals, maker of rare-disease drug Soliris. AstraZeneca bought Alexion for $1.8 billion in 2021.
AstraZeneca stock holds a Relative Strength Rating of 90, according to IBD Stock checkup.
Follow Reinhardt Krause on Twitter @reinhardtk_tech for updates on 5G wireless, artificial intelligence, cybersecurity and cloud computing.
YOU MIGHT ALSO LIKE:
Genetics, Alzheimer’s And AI — Why 2023 Could Be The Year For Biotech Stocks
IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today
Learn How To Time The Market With IBD’s ETF Market Strategy
How To Use The 10-Week Moving Average For Buying And Selling
Get Free IBD Newsletters: Market Prep | Tech Report | How To Invest
1/06/2023 See which stocks are showing resilience and strength with an IBD RS Rating upgrade.
1/06/2023 See which stocks are showing resilience and strength with an…
President Biden’s Job Approval jumped 10% to 44%. The Presidential Leadership Index rose 7.2% to 47.8, still below the 50 benchmark to indicate optimism.
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2023 Investor’s Business Daily, LLC. All rights reserved

source